1-(9H-芴-9-基)-2,2-二甲基-1-丙酮 | 134886-88-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 中文名称: 1-(9H-芴-9-基)-2,2-二甲基-1-丙酮
• 英文名称: ap-9-pivaloylfluorene
• 英文别名: 1-(9H-fluoren-9-yl)-2,2-dimethylpropan-1-one
• CAS: 134886-88-7
• 化学式: C₁₈H₁₈O
• 分子量: 250.34
• InChiKey: NAUVQRYTDICSRY-UHFFFAOYSA-N

物化性质

• 沸点：
  388.2±31.0 °C(Predicted)
• 密度：
  1.092±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2914399090

反应信息

• 作为反应物：
  描述：

  1-(9H-芴-9-基)-2,2-二甲基-1-丙酮 在 盐酸羟胺 、 potassium acetate 作用下， 以 乙醇 为溶剂， 反应 2.0h， 生成 ap-(Z)-9-pivaloylfluorene oxime
  参考文献：
  名称：

  Formation and identification of rotameric 9-pivaloylfluorene oximes. Structure of ap-(Z)-9-pivaloylfluorene oxime

  摘要：

  Reaction of hydroxylamine with sterically hindered ap-9-pivaloylfluorene (I) produced the rotameric antiperiplanar tap) and synperiplanar (sp) oximes (40% yield) as determined by H-1 NMR (CDCl3 or DMSO-d(6)) Their E/Z configurations (substituent geometry in C=N) could not be ascertained this way. Evaporation of solutions containing both rotamers consistently provided only one solid oxime which was shown to be the ap-(Z) oxime (IIa) [ap-(Z)-9-pivaloylfluorine oxime, C(18)H(19)NO1] by single-crystal X-ray diffraction. When crystalline (IIa) was redissolved (CDCl3 or DMSO-d(6)) both rotamers were present in ratios dependent on the concentration. The proximity of the oxime O atom to the fluorene-ring plane in (IIa), 2.598 Angstrom, results in a repulsion which raises the ground-state energy, thereby lowering the rotational barrier leading to the isomeric sp-(Z) oxime (IIIa). This repulsion is reflected in the larger angle, 123.9 (2)degrees (C9-C10-N1), in ap oxime (IIa), compared with 119.2 (4)degrees (C9-C10-O1) in the ap ketone (I). The rotational barrier (IIIa) --> (IIa) is also low because of the proximity of the tert-butyl group in (IIIa) to the fluorene-ring plane. Together these results demonstrate that rotational interconversion of (IIa) and (IIIa) occurs in solution at ambient temperatures at a rate which is slower than the NMR timescale, and that the crystal packing for (IIa) is more favorable than for (IIIa).

  DOI：

  10.1107/s0108270193014040

文献信息

• FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF
  申请人：Sarepta Therapeutics, Inc.

  公开号：US20140330006A1

  公开（公告）日：2014-11-06

  Functionally-modified oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3′ and/or 5′-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.

  提供了包含修改的亚单位间连接和/或修改的3'和/或5'-末端基团的功能修饰寡核苷酸类似物。所公开的化合物对于治疗需要抑制蛋白质表达或纠正异常mRNA剪接产物以产生有益治疗效果的疾病是有用的。
• Fluorenes as new molecular scaffolds for carbon–carbon σ-bond cleavage reaction: acylfluorenylation of arynes
  作者：Hiroto Yoshida、Takeshi Kishida、Masahiko Watanabe、Joji Ohshita

  DOI：10.1039/b814597k

  日期：——

  Acyl and fluorenyl moieties are facilely installed into neighbouring positions of aromatic skeletons via C-C bond cleavage reaction using arynes.

  通过使用芳烃的CC键裂解反应，可将酰基和芴基部分轻松地安装在芳族骨架的相邻位置。
• OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
  申请人：Hanson Gunnar J.

  公开号：US20120065169A1

  公开（公告）日：2012-03-15

  Oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3′ and/or 5′-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.

  提供了包含修改的亚单位连接和/或修改的3'和/或5'-末端基团的寡核苷酸类似物。所披露的化合物对于治疗需要抑制蛋白质表达或纠正异常mRNA剪接产物以产生有益治疗效果的疾病非常有用。
• MULTI-RING COMPOUNDS AND USES THEREOF
  申请人：Ohler Norman E.

  公开号：US20100249111A1

  公开（公告）日：2010-09-30

  Chemical agents, such as derivatives of hydroxy benzene moieties, and similar heterocyclic ring structures, including salts thereof, that act as anti-cancer and anti-tumor agents, especially where such agents modulate the activity of enzymes and structural polypeptides present in cells, such as cancer cells, or where the agents modulate levels of gene expression in cellular systems, including cancer cells, are disclosed, along with methods for preparing such agents, as well as pharmaceutical compositions containing such agents as active ingredients and methods of using these as therapeutic agents.

  本发明涉及化学制剂，例如羟基苯基衍生物及类似的杂环环结构，包括其盐，其作为抗癌和抗肿瘤制剂，特别是这些制剂调节细胞中的酶和结构多肽的活性，例如癌细胞，或这些制剂调节细胞系统中的基因表达水平，包括癌细胞等。本发明还涉及制备这些制剂的方法，以及包含这些制剂作为活性成分的制药组合物和使用这些制剂作为治疗剂的方法。
• PEPTIDE OLIGONUCLEOTIDE CONJUGATES
  申请人：Hanson Gunnar J.

  公开号：US20120289457A1

  公开（公告）日：2012-11-15

  Oligonucleotide analogues conjugated to carrier peptides are provided. The disclosed compounds are useful for the treatment of various diseases, for example diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.

  提供了与载体肽共轭的寡核苷酸类似物。所公开的化合物可用于治疗各种疾病，例如抑制蛋白质表达或校正异常的mRNA剪接产物可产生有益的治疗效果的疾病。